


**AMENDMENTS TO THE CLAIMS**

**Listing of Claims:**

1. (Previously presented) A compound of the formula I:



wherein:

R<sup>1</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
- (3) -O-C<sub>1</sub>-6alkyl, or
- (4) halogen;

R<sup>2</sup> is selected from the group consisting of:

- (1) C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
- (2) C<sub>3</sub>-7cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
- (3) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
  - (a) -C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with
    - (i) halogen,
    - (ii) phenyl,
    - (iii) -NR<sup>10</sup>R<sup>11</sup>,
  - (b) -O-C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with 1-6 fluoro,
  - (c) halogen,
  - (d) hydroxy,
  - (e) -SCF<sub>3</sub>,
  - (f) -SCHF<sub>2</sub>,
  - (g) -SCH<sub>3</sub>,

(h)  $\text{-CO}_2\text{R}^9$ ,

wherein  $\text{R}^9$  is independently selected from:

- (i) hydrogen,
- (ii)  $\text{-C}_1\text{-6alkyl}$ , which is unsubstituted or substituted with 1-6 fluoro,
- (iii) benzyl, and
- (iv) phenyl,
- (i)  $\text{-CN}$ ,
- (j)  $\text{-NR}^{10}\text{R}^{11}$ ,

wherein  $\text{R}^{10}$  and  $\text{R}^{11}$  are independently selected from:

- (i) hydrogen,
- (ii)  $\text{-C}_1\text{-6alkyl}$ , which is unsubstituted or substituted with hydroxy, 1-6 fluoro or  $\text{-NR}^{12}\text{R}^{13}$ , where  $\text{R}^{12}$  and  $\text{R}^{13}$  are independently selected from hydrogen and  $\text{-C}_1\text{-6alkyl}$ ,
- (iii)  $\text{-C}_5\text{-6cycloalkyl}$ ,
- (iv) -pyrrolidinyl, which is unsubstituted or substituted with  $\text{NR}^{10a}\text{R}^{11a}$ ,
- (v) benzyl, and
- (vi) phenyl,
- (k)  $\text{-CONR}^{10}\text{R}^{11}$ , and
- (l)  $\text{-NO}_2$ , and

(4) heterocycle, wherein heterocycle is selected from:

benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthypyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranolyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and

tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:

- (a) -C<sub>1-6</sub>alkyl,
- (b) -O-C<sub>1-6</sub>alkyl,
- (c) halogen,
- (d) hydroxy,
- (e) phenyl,
- (f) trifluoromethyl,
- (g) -OCF<sub>3</sub>,
- (h) -SCF<sub>3</sub>,
- (i) -SCHF<sub>2</sub>,
- (j) -SCH<sub>3</sub>,
- (k) -CO<sub>2</sub>R<sup>9</sup>,
- (l) -NR<sup>10</sup>R<sup>11</sup>, and
- (m) -CONR<sup>10</sup>R<sup>11</sup>;

R<sup>3</sup> is C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with halogen;

R<sup>4</sup> and R<sup>5</sup> are independently selected from the group consisting of:


- (1) hydrogen, and
- (2) C<sub>1-6</sub>alkyl,

or R<sup>4</sup> and R<sup>5</sup> may be joined together to form a cyclohexyl or cyclopentyl ring;

with the proviso that if R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen and R<sup>3</sup> is unsubstituted C<sub>1-6</sub>alkyl, R<sup>2</sup> is other than 2-methoxy-phenyl;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.


2. (Previously presented) The compound of Claim 1 of the formula Ia:



Ia

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.


3. (Previously presented) The compound of Claim 2 of the formula Ic:



Ic

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.


4. (Previously presented) The compound of Claim 1 of the formula Ib:



Ib

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

5. (Previously presented) The compound of Claim 4 of the formula Id:



and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

6. (Previously presented) The compound of Claim 1 wherein R<sup>1</sup> is hydrogen.
7. (Previously presented) The compound of Claim 1 wherein R<sup>1</sup> is fluoro.
8. (Previously presented) The compound of Claim 1 wherein R<sup>2</sup> is phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
  - (a) -C<sub>1-6</sub>alkyl,
  - (b) halogen,
  - (c) hydroxy,
  - (d) trifluoromethyl,
  - (e) -OCF<sub>3</sub>,
  - (f) -OCHF<sub>2</sub>,
  - (g) -SCF<sub>3</sub>,
  - (h) -SCHF<sub>2</sub>, and
  - (i) -NH<sub>2</sub>.
9. (Previously presented) The compound of Claim 8 wherein R<sup>2</sup> is phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
  - (a) halogen,
  - (b) trifluoromethyl, and
  - (c) -OCF<sub>3</sub>.
10. (Previously presented) The compound of Claim 9 wherein R<sup>2</sup> is phenyl, which is unsubstituted or substituted with halogen.
11. (Previously presented) The compound of Claim 1 wherein R<sup>2</sup> is pyridyl, which is unsubstituted or substituted with one or more halogen.

12. (Previously presented) The compound of Claim 1 wherein R<sup>3</sup> is C<sub>1-6</sub>alkyl.




13. (Previously presented) The compound of Claim 12 wherein R<sup>3</sup> is -(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>.







14. (Previously presented) The compound of Claim 1 wherein R<sup>4</sup> is hydrogen and R<sup>5</sup> is hydrogen.







15. (Previously presented) The compound of Claim 1 wherein R<sup>4</sup> is C<sub>1-3</sub>alkyl and R<sup>5</sup> is hydrogen.







16. (Previously presented) The compound of Claim 15 wherein R<sup>4</sup> is -CH<sub>3</sub> and R<sup>5</sup> is hydrogen.







17. (Previously presented) A compound which is selected from the group consisting of:























































and pharmaceutically acceptable salts thereof.

Claims 18-26 (Canceled)

27. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

28. (New) A method for inhibiting the glycine transporter GlyT1 in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

Serial No.: To Be Assigned  
Case No.: 21462P  
Page 20

29. (New) A method for treating a neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

30. (New) A method for treating schizophrenia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.